Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer.
Interleukin-2 (IL-2) was detected in urine but not serum of patients receiving intravesical bacille Calmette-Guerin (BCG) therapy for bladder cancer. IL-2 activity was neutralized by anti-IL-2 antibody. No IL-2 was detected in urine before BCG therapy or from control donors. BCG-induced urine IL-2 peaked 4-8 hr after treatment but was rarely observed after 24 hr. The presence of BCG-induced lymphokines may be associated with antitumor activity.